News
NHS approves new treatment for advanced womb cancer
The combination has been shown to stimulate the body’s immune system and kill off cancer cell growth

Hundreds of women with advanced womb cancer in England are to be offered a new “lifeline” option, as the NHS rolls out a new combination therapy that could halt the progression of the disease.
The NHS has agreed landmark commercial deals for two drugs from different manufacturers, which will be used in combination to treat advanced endometrial cancer in between 500 and 750 women each year.
Clinical trials have shown that pembrolizumab and lenvatinib used together can double the time taken for cancer to progress compared with the existing chemotherapy treatment, from just over three and half months to more than seven months.
In the trial, overall survival was also significantly longer for patients taking the combination therapy compared to existing chemotherapy treatments, with those taking pembrolizumab and lenvatinib living on average almost 19 months compared just under 12 months on existing chemotherapy.
Set for approval today by the National Institute for Health and Care Excellence (NICE), the combination has been shown to stimulate the body’s immune system and kill off cancer cell growth.
As part of the combination treatment, pembrolizumab is delivered intravenously every three or six weeks while lenvatinib is two pills taken once a day.
Currently, patients undergo chemotherapy treatment every three weeks, but unlike with chemotherapy, there is a far less significant risk of hair loss as a side effect of the new combination treatment.
Around 9,400 women are diagnosed with cancer in the womb every year, making it the fourth most common cancer in UK women.
While the treatment was initially rejected in draft guidance by NICE on the grounds of cost-effectiveness, the NHS has been able to use its commercial capabilities to negotiate a deal with the manufacturers, allowing the treatment to be made available to patients.
“It is fantastic news that this innovative combination therapy can now offer a new lifeline to hundreds of women living with advanced endometrial cancer, giving hope of precious extra time to live with a better quality of life,” said NHS national cancer director Professor Peter Johnson.
“Now in its 75th year, the NHS is leading the world in making the latest treatments available through its unique commercial capabilities and commitment to innovation on behalf of patients and their families across the country.”
Grace Teeling, a 33-year-old from Bristol who was diagnosed with advanced stage three womb cancer in 2019, said: “I have been incredibly fortunate to receive treatment for the past two years and I had a really good response, which means there is currently no evidence of cancer on my recent scans,” she said.
“It has enabled me to thrive despite having an advanced and incurable cancer diagnosis.
“I am able to work, travel, socialise and exercise, including paddleboarding, which I may not have been able to do on chemotherapy. I am delighted others will now be able to access this treatment as I don’t think I would be alive today if I hadn’t.”
Professor Emma Crosbie, chair of trustees of Peaches Womb Cancer Trust, said: “This innovative new treatment regimen will benefit patients with advanced or recurrent endometrial cancer, who currently have very few effective anti-cancer treatments available to them.
“Every year, many people are facing a diagnosis of advanced or recurrent womb cancer, and the frightening reality of very few treatment options that can improve their survival and quality of life.
“Those affected by womb cancer deserve more treatment options, but we hope that this is just the first step towards wider availability of more effective treatment options for those affected by this devastating cancer.”
David Long, head of oncology at MSD UK, which manufactures pembrolzimab, said: “Endometrial cancer is one of the few cancers with rising incidence and mortality, and historically there has been limited treatment options for people with advanced stages of the disease.
“We are therefore very pleased that a new treatment option has been made available to patients which will help address this unmet need.
“We are proud to have worked alongside Eisai, NICE and NHS England to ensure patients can access this treatment.”
The combination treatment will be funded by the NHS and will be offered to all eligible women who have previously received treatment for advanced or recurrent endometrial cancer.
Adolescent health
Newly-launched Female Health Hub will support grassroots football players

A new Female Health Hub launched by the English FA will support women and girls in grassroots football in England with trusted advice on health issues affecting play.
The hub brings together expert-backed guidance, practical tools and player insights in one place, giving women and girls practical advice and reassurance on female health in football.
It has four core aims: to help women and girls better understand their bodies and how female health affects performance and participation, to educate players on key health topics and when to seek further advice or support, to provide practical strategies to help navigate common female health challenges, and to help break down taboos and normalise conversations around female health in football.
Users of the hub will also be able to hear directly from members of the England women’s national team, who share their own experiences of navigating female health matters while playing at the highest level of the game.
“Our ambition is to create a game where women and girls can thrive,” said Sue Day, the FA’s director of women’s football.
“To achieve that, it’s essential that players feel supported in environments that understand and respond to their female health needs.
“We’ve heard directly from grassroots players that they want better information and support around female health, but that they often don’t know where to find it.
“The launch of the Female Health Hub marks an important step in changing the landscape.
“We want every player to feel confident in her own skin and supported without judgment, so she can feel empowered by her body, rather than held back by it.”
The platform was launched following research conducted by the FA that highlighted the need for better education and support around female health in football.
According to the FA, 88 per cent of adult players surveyed said their menstrual cycle has an impact on their ability to train or play, but 86 per cent reported they had never received education about the menstrual cycle in relation to football performance and training.
The research also found 64 per cent of women experience issues related to sports bras or breast health while playing football, despite sports bras being considered one of the most important pieces of playing kit.
Players also expressed strong interest in learning more about injury prevention, at 87 per cent, nutrition, at 84 per cent, and mental health, at 77 per cent, in relation to female health.
The first phase of the Female Health Hub focuses on three of the most requested topics: menstrual health, breast health and injury resilience, with further content to follow, including nutrition and pelvic health guidance.
Pregnancy
Women’s health strategy a ‘missed opportunity,’ RCM says
Fertility
Genetic carrier screening before pregnancy: What to know

Article produced in association with London Pregnancy Clinic and Jeen Health
For the majority of couples planning a pregnancy, genetic testing is not something they think about until a problem arises.
Pre-conception genetic carrier screening challenges this approach by identifying risk before pregnancy begins.
As panel sizes have grown and at-home testing options have become widely available, carrier screening is transitioning from a niche clinical referral into a mainstream component of reproductive planning.
What Carrier Screening Tests For
Being a carrier of a genetic condition means carrying one copy of a variant in a gene associated with that condition, without being affected by it.
In most cases, carriers are entirely unaware of their status.
The clinical significance of carrier status emerges when both members of a couple carry a variant in the same gene: in this scenario, each pregnancy carries a one in four chance of resulting in a child who inherits two copies of the variant and is affected by the condition.
The conditions most frequently included in expanded carrier screening panels include cystic fibrosis, spinal muscular atrophy (SMA), fragile X syndrome, sickle cell disease, and a range of metabolic and enzyme deficiency disorders.
The Beacon 787 carrier test, offered by Jeen Health, screens for 787 conditions from a single sample, making it one of the most comprehensive panels currently available to UK families.
Who Is Most Likely to Benefit
Any couple planning a pregnancy can consider carrier screening. It is particularly relevant for:
- Couples with a family history of a known inherited condition
- Those from populations with higher carrier frequencies for specific conditions, including Ashkenazi Jewish, South Asian and African communities
- Couples pursuing fertility treatment, where genetic information informs treatment planning
- Those who wish to have the most complete picture of their reproductive health before conception
Importantly, being a carrier of a condition does not mean a child will be affected. It means there is a defined statistical risk that can be quantified, discussed and planned for with appropriate clinical support.
How the Test Is Performed
Carrier screening is typically carried out on a blood or saliva sample.
For at-home options such as the testing offered by Jeen Health, a cheek swab collection kit is dispatched to the patient, the sample is returned by post, and results are delivered digitally within a defined turnaround period.
In-clinic carrier testing may use a blood draw and provides the advantage of immediate access to a clinical consultation at the point of result delivery.
London Pregnancy Clinic offers genetics counselling through its partnership with Jeen Health, allowing couples to receive and contextualise carrier test results with expert support.
Genetic counselling before and after testing is recommended by Genomics England as a standard component of any genomic testing pathway.
What Happens If Both Partners Are Carriers
If both partners are identified as carriers for the same autosomal recessive condition, they are typically offered further counselling to discuss their options.
These may include proceeding naturally with an awareness of the risk, using prenatal diagnosis (CVS or amniocentesis) during pregnancy to test the fetus, or pursuing preimplantation genetic testing (PGT) in the context of IVF, which allows unaffected embryos to be selected before transfer.
The purpose of identifying carrier status before pregnancy is to give couples time to consider these options without the added pressure of an ongoing pregnancy.
Knowledge of carrier status does not remove reproductive choices; it expands the information available when making them.
The Role of Pre-Conception Services
Carrier screening sits within a broader category of pre-conception care that includes fertility assessments, general health optimisation and, where relevant, management of existing conditions before pregnancy begins.
London Pregnancy Clinic offers pre-conception services encompassing fertility investigations, genetics counselling and carrier testing as part of an integrated 0th trimester approach, allowing couples to address genetic and clinical risk factors before their pregnancy starts rather than after.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.
Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.
This piece was produced in association with London Pregnancy Clinic and Jeen Health, which provided background clinical information for editorial purposes.
Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Entrepreneur2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Menopause4 weeks agoCalifornia plans US$3.4m menopause care overhaul
Menopause3 weeks agoWatchdog bans five ads for women’s heath claims
Pregnancy2 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Menopause3 weeks agoMenopause has no lasting impact on cognition, research finds
News2 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Entrepreneur3 weeks agoWHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
Opinion3 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up














